Duncan I Jodrell

List of Publications by Year
in descending order

22 papers	1,997 citations	759233 12 h-index	713466 21 g-index
22 all docs	22 docs citations	22 times ranked	4836 citing authors

#	Article	IF	Citations
1	Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics, 2016, 32, 2866-2868.	4.1	499
2	*nab*-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer. Cancer Discovery, 2012, 2, 260-269.	9.4	359
3	Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. Cell Metabolism, 2016, 24, 672-684.	16.2	264
4	CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12325-12330.	7.1	207
5	Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses. Journal of Experimental Medicine, 2019, 216, 1986-1998.	8.5	153
6	Design, Synthesis, and Biological Evaluation of an Allosteric Inhibitor of HSET that Targets Cancer Cells with Supernumerary Centrosomes. Chemistry and Biology, 2013, 20, 1399-1410.	6.0	94
7	The ATR Inhibitor AZD6738 Synergizes with Gemcitabine *In Vitro* and *In Vivo* to Induce Pancreatic Ductal Adenocarcinoma Regression. Molecular Cancer Therapeutics, 2018, 17, 1670-1682.	4.1	79
8	New Model for Estimating Glomerular Filtration Rate in Patients With Cancer. Journal of Clinical Oncology, 2017, 35, 2798-2805.	1.6	78
9	Understanding the Complexity of Porous Graphitic Carbon (PGC) Chromatography: Modulation of Mobile-Stationary Phase Interactions Overcomes Loss of Retention and Reduces Variability. Analytical Chemistry, 2016, 88, 6190-6194.	6.5	59
10	Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. Nature Communications, 2019, 10, 5167.	12.8	52
11	Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 6742-6755.	7.0	45
12	Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models. British Journal of Cancer, 2020, 123, 1424-1436.	6.4	40
13	Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition–Induced Hypertension. Hypertension, 2021, 77, 1591-1599.	2.7	13
14	Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy. PLoS Computational Biology, 2017, 13, e1005529.	3.2	12
15	Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach. EBioMedicine, 2021, 68, 103396.	6.1	9
16	T Cell–Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer. Molecular Cancer Therapeutics, 2021, 20, 1926-1940.	4.1	9
17	Early Neutrophilia Marked by Aerobic Glycolysis Sustains Host Metabolism and Delays Cancer Cachexia. Cancers, 2022, 14, 963.	3.7	9
18	Multicenter Validation of the CamGFR Model for Estimated Glomerular Filtration Rate. JNCI Cancer Spectrum, 2019, 3, pkz068.	2.9	6

#	Article	IF	Citations
19	Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report. BMC Cancer, 2020, 20, 38.	2.6	6
20	Cancer Immunotherapy Trials Underutilize Immune Response Monitoring. Oncologist, 2018, 23, 116-117.	3.7	3
21	The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI data. Magnetic Resonance Imaging, 2015, 33, 246-251.	1.8	1
22	Abstract 6103: Reshaping the myeloid-dependent pro-tumorigenic microenvironment in PDAC by targeting the extracellular adenosine pathway: A therapeutic opportunity. Cancer Research, 2022, 82, 6103-6103.	0.9	0